Claims for Patent: 12,453,726

Summary for Patent: 12,453,726

Title:	Methods of using factor B inhibitors
Abstract:	Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.
Inventor(s):	Irina Baltcheva, Peter End, Julie Marie-Pomme Gabrielle MILOJEVIC
Assignee:	Novartis AG
Application Number:	US18/595,759
Patent Claims:	1. A method of normalizing intravascular hemolysis (IVH) and/or extravascular hemolysis (EVH) in a subject in need thereof, the method comprising orally administering to the subject 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl) methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof, at a dose of about 200 mg twice daily (b.i.d.), thereby treating the subject, wherein the dosing amount refers to the anhydrous free base of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl) methyl)piperidin-2-yl))benzoic acid hydrochloride. 2. The method of claim 1, wherein normalizing intravascular hemolysis (IVH) and/or extravascular hemolysis (EVH) comprises increasing hemoglobin levels in the subject by about 2 g/dL or more as compared to hemoglobin levels in the subject prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein normalizing intravascular hemolysis (IVH) and/or extravascular hemolysis (EVH) comprises increasing the haptoglobin level, decreasing reticulocytes level, or decreasing bilirubin level, in the subject as compared to the level of haptoglobin, reticulocytes, or bilirubin in the subject prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl) methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein the level of haptoglobin is increased by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or about 90%. 5. The method of claim 3, wherein the level of bilirubin or reticulocytes is reduced by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or about 90%. 6. A method of treating intravascular hemolysis (IVH) in a subject in need thereof, the method comprising orally administering to the subject 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof, at a dose of about 200 mg twice daily (b.i.d.), thereby treating the subject, wherein the dosing amount refers to the anhydrous free base of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid hydrochloride, wherein treating intravascular hemolysis (IVH) comprises increasing hemoglobin levels in the subject by about 2 g/dL or more as compared to hemoglobin levels in the subject prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 7. The method of claim 6, wherein treating intravascular hemolysis (IVH) comprises increasing hemoglobin levels in the subject in the absence of receiving one or more red blood cell (RBC) transfusion(s). 8. The method of claim 6, wherein treating intravascular hemolysis (IVH) comprises reducing the level of lactate hydrogenase (LDH) in the subject, as compared to the level of LDH in the subject prior to administration 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 9. The method of claim 8, wherein the LDH level in the subject, is reduced by at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95%. 10. A method of treating extravascular hemolysis (EVH) in a subject in need thereof, the method comprising orally administering to the subject 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof, at a dose of about 200 mg twice daily (b.i.d.), thereby treating the subject, wherein the dosing amount refers to the anhydrous free base of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid hydrochloride, wherein treating extravascular hemolysis (EVH) comprises increasing hemoglobin levels in the subject by about 2 g/dL or more as compared to hemoglobin levels in the subject prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 11. The method of claim 10, wherein treating extravascular hemolysis (EVH) comprises increasing hemoglobin levels in the subject in the absence of receiving one or more red blood cell (RBC) transfusion(s). 12. The method of claim 10, wherein treating extravascular hemolysis (EVH), comprises reducing the level of bilirubin or reticulocytes in the subject, or increasing the level of haptoglobin, as compared to the level of bilirubin, reticulocytes, or haptoglobin in the subject, prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 13. The method of claim 12, wherein the level of bilirubin or reticulocytes is reduced by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or about 90%. 14. The method of claim 1, wherein the subject has been previously treated with an anti-C5 therapy prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 15. The method of claim 14, wherein the anti-C5 therapy is an anti-C5 monoclonal antibody therapy. 16. The method of claim 1, wherein the subject has residual anemia. 17. The method of claim 1, wherein hemoglobin levels, haptoglobin levels, reticulocyte levels, and/or bilirubin levels of the subject, are evaluated prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 18. The method of claim 16, wherein the hemoglobin levels of the subject are less than or equal to about 10 g/dL, prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)) benzoic acid or a pharmaceutically acceptable salt thereof. 19. The method of claim 1, wherein hemolysis is PNH associated hemolysis. 20. The method of claim 1, wherein the method comprises achieving a sustained increase in hemoglobin level. 21. The method of claim 1, wherein the method comprises achieving a sustained increase in hemoglobin level to greater than or equal to about 12 g/dL. 22. The method of claim 1, wherein the method comprises increasing hemoglobin levels in the subject in the absence of receiving one or more red blood cell (RBC) transfusion(s). 23. The method of claim 1, wherein the subject has received RBC transfusions. 24. The method of claim 1, wherein the subject has been vaccinated prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof prior vaccination against Neisseria meningitidis (types A, C, Y and W-135). 25. The method of claim 1, wherein efficacy of treatment is determined by measuring the hemoglobin levels in the subject as compared to baseline. 26. The method of claim 6, wherein the subject has been previously treated with an anti-C5 therapy prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 27. The method of claim 26, wherein the anti-C5 therapy is an anti-C5 monoclonal antibody therapy. 28. The method of claim 6, wherein the subject has residual anemia. 29. The method of claim 6, wherein hemoglobin levels, haptoglobin levels, reticulocyte levels, and/or bilirubin levels of the subject, are evaluated prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 30. The method of claim 28, wherein the hemoglobin levels of the subject are less than or equal to about 10 g/dL, prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 31. The method of claim 6, wherein hemolysis is PNH associated hemolysis. 32. The method of claim 6, wherein the method comprises achieving a sustained increase in hemoglobin level. 33. The method of claim 6, wherein the method comprises achieving a sustained increase in hemoglobin level to greater than or equal to about 12 g/dL. 34. The method of claim 6, wherein the method comprises increasing hemoglobin levels in the subject in the absence of receiving one or more red blood cell (RBC) transfusion(s). 35. The method of claim 6, wherein the subject has received RBC transfusions. 36. The method of claim 6, wherein the subject has been vaccinated prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof prior vaccination against Neisseria meningitidis (types A, C, Y and W-135). 37. The method of claim 6, wherein efficacy of treatment is determined by measuring the hemoglobin levels in the subject as compared to baseline. 38. The method of claim 10, wherein the subject has been previously treated with an anti-C5 therapy prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 39. The method of claim 38, wherein the anti-C5 therapy is an anti-C5 monoclonal antibody therapy. 40. The method of claim 10, wherein the subject has residual anemia. 41. The method of claim 10, wherein hemoglobin levels, haptoglobin levels, reticulocyte levels, and/or bilirubin levels of the subject, are evaluated prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 42. The method of claim 41, wherein the hemoglobin levels of the subject are less than or equal to about 10 g/dL, prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof. 43. The method of claim 10, wherein hemolysis is PNH associated hemolysis. 44. The method of claim 10, wherein the method comprises achieving a sustained increase in hemoglobin level. 45. The method of claim 10, wherein the method comprises achieving a sustained increase in hemoglobin level to greater than or equal to about 12 g/dL. 46. The method of claim 10, wherein the method comprises increasing hemoglobin levels in the subject in the absence of receiving one or more red blood cell (RBC) transfusion(s). 47. The method of claim 10, wherein the subject has received RBC transfusions. 48. The method of claim 10, wherein the subject has been vaccinated prior to administration of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof prior vaccination against Neisseria meningitidis (types A, C, Y and W-135). 49. The method of claim 10, wherein efficacy of treatment is determined by measuring the hemoglobin levels in the subject as compared to baseline.